

PROVIDER BULLETIN

PROVIDER INFORMATION



March 1, 2024

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-758	Fractional Carbon Dioxide (CO ₂) Laser Ablation Treatment of Hypertrophic Scars or Keloids for Functional Improvement
MP-070	Locoregional Therapies for Hepatocellular Carcinoma and Metastatic Liver Carcinoma and Metastatic Carcinoid Tumors of the Liver
MP-483	Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-90744	Casgevy (exagamglogene autotemcel)
PH-90743	Lyfgenia (lovotibeglogene autotemcel)
PH-90513	Adakveo (crizanlizumab-tmca)

Policy #	Policy Title
PH-90345	Factor VIII_vWF: Alphanate, Humate-P, Wilate
PH-90421	Gamifant (emapalumab-lzg)nt (emapalumab-lzg)
PH-90514	Givlaari (givosiran)
PH-90350	Luxturna (voretigene neparvovec-rzly)
PH-90579	Oxlumo (lumasiran)
PH-90648	Rethymic (allogeneic processed thymus tissue-agdc)
PH-90512	Scenesse (afamelanotide)
PH-90525	Tepezza (teprotumumab-trbw)
PH-90687	Tzielid (teplizumab-mzwv)